Trial Profile
A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Goserelin; Leuprorelin; Tamoxifen
- Indications Male breast cancer
- Focus Therapeutic Use
- Acronyms MALE
- 22 Jun 2018 Status changed from active, no longer recruiting to completed.
- 09 Dec 2017 Results assessing safety and efficacy, presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.